Phaseline

Targets › TNFSF14

TNFSF14 (Tumor necrosis factor ligand superfamily member 14): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Cytokine that binds to TNFRSF3/LTB and TNFRSF14/HVEM and plays major roles in immune system regulation. Upon binding to TNFRSF14/HVEM, delivers costimulatory signals to T cells, leading to T cell proliferation and IFNG production. (UniProt, O43557)

Open in Phaseline: the race on TNFSF14, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheEnglumafusp alfa
CD19-targeted 4-1BB ligand
CD19, TNFSF14Phase 1Lymphoma, Non-HodgkinMar 2027

Conditions

Lymphoma, Non-Hodgkin (1)

Modalities

mixed (1)

Companies

Roche (1)

Related targets

CD19 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.